knowledge -WSS

knowledge

author：comprehensive 2025-10-02 12:01:43 - browse：6

Sage Therapeutics, a biotech developing an experimental treatment for postpartum depression, this week trumpeted strong results from a clinical trial, which cheered investors and pushed up its stock price. But outside the lab, the company’s aggressive efforts to raise awareness of postpartum depression have proved divisive.

The campaign’s message: “When it comes to postpartum depression, silence sucks.” It features close-up photos of distressed, tearful women who can’t speak — because they have pacifiers stuck in their mouths.

The images have been plastered on bus stops, buses, conference booths, and on a dedicated website. The ads don’t specifically mention Sage’s drug, which still needs further testing before the company can bring it to the Food and Drug Administration for possible approval. Instead, they urge women to talk “openly and honestly” about postpartum depression. An estimated 600,000 women in the U.S. alone experience symptoms, which range from insomnia and irritability to difficulty bonding with their baby.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Alkermes shareholders re
Next article： Ransomware attacks on hospitals: Study outlines patient impact

hotspot

focus

WSS

Gain of function research would be limited under House proposal

5 takeaways from STAT's examination of Zynex Medical

Ransomware attacks on hospitals: Study outlines patient impact

Readout Newsletter: Bayer's future, Merck Caraway acquisition, etc

David Sabatini, ex

Readout Newsletter: What is Casgevy? Does Wegovy hurt muscle?

explore

knowledge

knowledge

How to save PrEP access — and even expand it

Curing rare childhood diseases will falter unless Congress steps up

Activists slam private health insurers over coverage restrictions

Stephen Quake on the Chan Zuckerberg quest to conquer disease

Tori Bowie and the unacceptable rates of Black maternal death

Readout Newsletter: Bayer study halts, Carmot to IPO, and more

Hepatitis C has a cure — but many Americans still lack access to it

Buoyed by wins on obesity, Novo Nordisk eyes heart disease

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Readout Newsletter: Bayer's future, Merck Caraway acquisition, etc

explore

Readout Newsletter: The latest at Gilead, Catalent, and the NIH

Deposition: Sackler embraced plan to conceal OxyContin’s strength

Readout Newsletter: Bayer study halts, Carmot to IPO, and more

Gain of function research would be limited under House proposal

ALS patient reclaims some autonomy thanks to wearable 'robot'

Study: Why relieving medical debt did not improve financial outcomes

knowledge

hotspot

focus

hotspot